280 related articles for article (PubMed ID: 29599065)
21. Modeling, synthesis and biological evaluation of potential retinoid X receptor (RXR) selective agonists: novel analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene).
Wagner CE; Jurutka PW; Marshall PA; Groy TL; van der Vaart A; Ziller JW; Furmick JK; Graeber ME; Matro E; Miguel BV; Tran IT; Kwon J; Tedeschi JN; Moosavi S; Danishyar A; Philp JS; Khamees RO; Jackson JN; Grupe DK; Badshah SL; Hart JW
J Med Chem; 2009 Oct; 52(19):5950-66. PubMed ID: 19791803
[TBL] [Abstract][Full Text] [Related]
22. Next-generation retinoid X receptor agonists increase ATRA signaling in organotypic epithelium cultures and have distinct effects on receptor dynamics.
Melo N; Belyaeva OV; Berger WK; Halasz L; Yu J; Pilli N; Yang Z; Klyuyeva AV; Elmets CA; Atigadda V; Muccio DD; Kane MA; Nagy L; Kedishvili NY; Renfrow MB
J Biol Chem; 2023 Jan; 299(1):102746. PubMed ID: 36436565
[TBL] [Abstract][Full Text] [Related]
23. Statin-induced depletion of geranylgeranyl pyrophosphate inhibits cell proliferation by a novel pathway of Skp2 degradation.
Vosper J; Masuccio A; Kullmann M; Ploner C; Geley S; Hengst L
Oncotarget; 2015 Feb; 6(5):2889-902. PubMed ID: 25605247
[TBL] [Abstract][Full Text] [Related]
24. ECPIRM, a Potential Therapeutic Agent for Cutaneous T-Cell Lymphoma, Inhibits Cell Proliferation and Promotes Apoptosis via a JAK/STAT Pathway.
Yang H; Ma P; Cao Y; Zhang M; Li L; Wei J; Tao L; Qian K
Anticancer Agents Med Chem; 2018; 18(3):401-411. PubMed ID: 28356009
[TBL] [Abstract][Full Text] [Related]
25. Role of bexarotene in the treatment of cutaneous T-cell lymphoma: the clinical and immunological sides.
Pileri A; Delfino C; Grandi V; Pimpinelli N
Immunotherapy; 2013 Apr; 5(4):427-33. PubMed ID: 23557425
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of Integrin αVβ3 Signaling Improves the Antineoplastic Effect of Bexarotene in Cutaneous T-Cell Lymphoma.
Cayrol F; Revuelta MV; Debernardi M; Paulazo A; Phillip JM; Zamponi N; Sterle H; Díaz Flaqué MC; Magro C; Marullo R; Mulvey E; Ruan J; Cremaschi GA; Cerchietti L
Mol Cancer Ther; 2022 Sep; 21(9):1485-1496. PubMed ID: 35793463
[TBL] [Abstract][Full Text] [Related]
27. Central hypothyroidism associated with retinoid X receptor-selective ligands.
Sherman SI; Gopal J; Haugen BR; Chiu AC; Whaley K; Nowlakha P; Duvic M
N Engl J Med; 1999 Apr; 340(14):1075-9. PubMed ID: 10194237
[TBL] [Abstract][Full Text] [Related]
28. Methods to Assess Activity and Potency of Rexinoids Using Rapid Luciferase-Based Assays: A Case Study with NEt-TMN.
Jurutka PW; Wagner CE
Methods Mol Biol; 2019; 2019():95-108. PubMed ID: 31359391
[TBL] [Abstract][Full Text] [Related]
29. RARα/RXR synergism potentiates retinoid responsiveness in cutaneous T-cell lymphoma cell lines.
Wang L; DeMarco SS; Peaks MS; Maiorana-Boutilier AL; Chen J; Crouch MJ; Shewchuk BM; Shaikh SR; Phillips CM; Bridges LC
Exp Dermatol; 2017 Nov; 26(11):1004-1011. PubMed ID: 28370539
[TBL] [Abstract][Full Text] [Related]
30. Defining the communication between agonist and coactivator binding in the retinoid X receptor α ligand binding domain.
Boerma LJ; Xia G; Qui C; Cox BD; Chalmers MJ; Smith CD; Lobo-Ruppert S; Griffin PR; Muccio DD; Renfrow MB
J Biol Chem; 2014 Jan; 289(2):814-26. PubMed ID: 24187139
[TBL] [Abstract][Full Text] [Related]
31. Caffeic acid phenethyl ester induced cell cycle arrest and growth inhibition in androgen-independent prostate cancer cells via regulation of Skp2, p53, p21Cip1 and p27Kip1.
Lin HP; Lin CY; Huo C; Hsiao PH; Su LC; Jiang SS; Chan TM; Chang CH; Chen LT; Kung HJ; Wang HD; Chuu CP
Oncotarget; 2015 Mar; 6(9):6684-707. PubMed ID: 25788262
[TBL] [Abstract][Full Text] [Related]
32. Preclinical Evaluation of UAB30 in Pediatric Renal and Hepatic Malignancies.
Waters AM; Stewart JE; Atigadda VR; Mroczek-Musulman E; Muccio DD; Grubbs CJ; Beierle EA
Mol Cancer Ther; 2016 May; 15(5):911-21. PubMed ID: 26873726
[TBL] [Abstract][Full Text] [Related]
33. Retinoic acid stabilizes p27Kip1 in EBV-immortalized lymphoblastoid B cell lines through enhanced proteasome-dependent degradation of the p45Skp2 and Cks1 proteins.
Zancai P; Dal Col J; Piccinin S; Guidoboni M; Cariati R; Rizzo S; Boiocchi M; Maestro R; Dolcetti R
Oncogene; 2005 Apr; 24(15):2483-94. PubMed ID: 15735731
[TBL] [Abstract][Full Text] [Related]
34. Absence of modulation of CD4+CD25 regulatory T cells in CTCL patients treated with bexarotene.
Knol AC; Quéreux G; Brocard A; Ballanger F; Khammari A; Nguyen JM; Dréno B
Exp Dermatol; 2010 Aug; 19(8):e95-102. PubMed ID: 19845755
[TBL] [Abstract][Full Text] [Related]
35. Skp2 Inhibitors: Novel Anticancer Strategies.
Lee Y; Lim HS
Curr Med Chem; 2016; 23(22):2363-79. PubMed ID: 27160538
[TBL] [Abstract][Full Text] [Related]
36. Rexinoids modulate steroid and xenobiotic receptor activity by increasing its protein turnover in a calpain-dependent manner.
Pettersson F; Hanna N; Lagodich M; Dupéré-Richer D; Couture MC; Choi C; Miller WH
J Biol Chem; 2008 Aug; 283(32):21945-52. PubMed ID: 18544536
[TBL] [Abstract][Full Text] [Related]
37. Salinomycin induces cell death via inactivation of Stat3 and downregulation of Skp2.
Koo KH; Kim H; Bae YK; Kim K; Park BK; Lee CH; Kim YN
Cell Death Dis; 2013 Jun; 4(6):e693. PubMed ID: 23807222
[TBL] [Abstract][Full Text] [Related]
38. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results.
Duvic M; Hymes K; Heald P; Breneman D; Martin AG; Myskowski P; Crowley C; Yocum RC;
J Clin Oncol; 2001 May; 19(9):2456-71. PubMed ID: 11331325
[TBL] [Abstract][Full Text] [Related]
39. The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer.
Moerland JA; Zhang D; Reich LA; Carapellucci S; Lockwood B; Leal AS; Krieger-Burke T; Aleiwi B; Ellsworth E; Liby KT
Sci Rep; 2020 Dec; 10(1):22244. PubMed ID: 33335263
[TBL] [Abstract][Full Text] [Related]
40. Proteasome inhibitor MG-132 mediated expression of p27Kip1 via S-phase kinase protein 2 degradation induces cell cycle coupled apoptosis in primary effusion lymphoma cells.
Hussain AR; Ahmed M; Ahmed SO; Al-Thari S; Khan AS; Razack S; Platanias LC; Al-Kuraya KS; Uddin S
Leuk Lymphoma; 2009 Jul; 50(7):1204-13. PubMed ID: 19557642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
